In various tumour cell lines the peptide bradykinin B2receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist
- 1 December 2000
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 131 (8) , 1553-1560
- https://doi.org/10.1038/sj.bjp.0703764
Abstract
This study examined the mitogenic effects of bradykinin (BK, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), the peptide bradykinin B(2) receptor antagonist Hoe 140 (D-Arg(0)[Hyp(3)-Thi(6)-D-Tic(7)-Oic(8)]BK, and the orally active, nonpeptide B(2) receptor antagonist FR 173657 ((E)-3-(6-acetamido-3-pyridyl)-N-[N-2-4-dichloro-3-[(2-methyl-8-quino linyl) oxymethyl]phenyl]-N-methylaminocarbonyl-methyl]acrylamide) in three different human tumour cell lines: the small cell lung carcinoma (SCLC) cell line H-69, the breast carcinoma cell line EFM-192A, and the colon carcinoma cell line SW-480. In these cell lines activation of mitogen-activated protein kinase (MAPK) is involved in BK-induced stimulation of cell proliferation and may be mediated by both G(q) proteins (SW-480) and G(i) proteins (EFM-192A; H-69). In these cells BK as well as Hoe 140 increased the rate of DNA synthesis measured with the [(3)H]-thymidine uptake assay. Hoe 140 did neither antagonize nor potentiate the effect of BK. FR 173657 did not stimulate [(3)H]-thymidine incorporation but clearly antagonized the mitogenic effects of BK as well as Hoe 140. In H-69 cells, FR 173657 induced a decrease in the basal rate of DNA synthesis. In all three cell lines BK and Hoe 140 stimulated the activity of MAPK. Their effect on MAPK activity was completely abolished by FR 173657 which itself did not increase the activity of MAPK. In H-69 cells, the basal activity of MAPK was slightly inhibited by FR 173657. In the cell lines SW-480 and H-69 both BK and Hoe 140 but not FR 173657 stimulated phosphatidylinositol hydrolysis. In H-69 cells, FR 173657 decreased basal inositol phosphate formation. Our results show that in certain tumour cell lines the classical peptide B(2) receptor antagonist, Hoe 140, may act as mitogenic B(2) receptor agonist whereas the nonpeptide B(2) receptor antagonist, FR 173657, does not. In H-69 cells FR 173657 was found to exhibit properties of an inverse agonist.Keywords
This publication has 32 references indexed in Scilit:
- A Novel Mitogenic Signaling Pathway of Bradykinin in the Human Colon Carcinoma Cell Line SW-480 Involves Sequential Activation of a Gq/11 Protein, Phosphatidylinositol 3-Kinase β, and Protein Kinase CεJournal of Biological Chemistry, 1998
- Effects of a nonpeptide bradykinin B2receptor antagonist, FR167344, on differentin vivoanimal models of inflammationBritish Journal of Pharmacology, 1997
- Cloning and Functional Characterization of the Ornithokinin ReceptorPublished by Elsevier ,1997
- The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657British Journal of Pharmacology, 1997
- Mutations in the B2 Bradykinin Receptor Reveal a Different Pattern of Contacts for Peptidic Agonists and Peptidic AntagonistsPublished by Elsevier ,1996
- A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activationNature, 1996
- Bradykinin antagonists: Development and applicationsBiopolymers, 1995
- Analysis of the antagonistic actions of HOE 140 and other novel bradykinin analogues on the guinea-pig ileumEuropean Journal of Pharmacology, 1992
- Bradykinin receptors: Pharmacological properties and biological rolesPharmacology & Therapeutics, 1992
- Competitive antagonists of bradykininPeptides, 1985